Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study

Gastroesophageal Reflux Disease Clinical Trial

— RESPECT  

Official title:

A Randomized Controlled Trial Comparing Transoral Incisionless Fundoplication (TIF) Using EsophyX With Sham Procedure for the Treatment of PPI Dependent GERD Compared With Sham and Placebo Controls

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01136980
• Other study ID #: D01010
• Status: Completed
• Phase: N/A
• Start date: April 2011
• Est. completion date: March 2018

Study information

• Verified date: December 2021
• Source: EndoGastric Solutions
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to evaluate the relative merits, safety and effectiveness of the EsophyX transoral device in performing an advanced TIF procedure in patients with "troublesome symptoms" as defined by the Montreal consensus definition while on PPIs compared with sham and placebo controls.

Description:

Primary Effectiveness Endpoint: A clinically significant reduction in GERD symptoms, specifically "Troublesome" regurgitation with or without heartburn assessed by the Reflux Disease Questionnaire (RDQ).

Troublesome symptoms are those which occur a minimum of 2 days a week and are at least moderate in severity.

Secondary Effectiveness Endpoint: The normalization of esophageal acid exposure at 6 months and a clinically significant reduction in PPI usage at 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 129
• Est. completion date: March 2018
• Est. primary completion date: April 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age 18-80 years

• Dependent upon daily PPIs for > 6 months

• Troublesome symptoms, specifically heartburn or regurgitation, while on 40 mg of omeprazole or equivalent.

Troublesome heartburn or regurgitation symptoms are those which occur a minimum of 2-3 days a week and are at least moderate in severity.

• Abnormal ambulatory pH study off PPI therapy for 7 days.

• Normal or near normal esophageal motility (by manometry)

• Hiatal hernia axial height is no larger than 2 cm and the transverse dimension should not exceed 2.5 cm

• Patient willing to cooperate with post-operative dietary recommendations and assessment tests

• Signed informed consent

Exclusion Criteria:

• BMI > 35

• Hiatal hernia > 2 cm

• Esophagitis Los Angeles grade C or D

• Esophageal ulcer

• Esophageal stricture

• Esophageal motility disorder

• Pregnancy or plans for pregnancy in the next 12 months (in females)

• Immunosuppression

• ASA > 2

• Portal hypertension and/or varices

• History of previous resective gastric or esophageal surgery, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis

• Active gastro-duodenal ulcer disease

• Gastric outlet obstruction or stenosis

• Severe gastroparesis or delayed gastric emptying confirmed by solid-phase gastric emptying study if patient complains of postprandial satiety during assessment

• Coagulation disorders

• Interprocedural determination of anatomical presentation which in the opinion of the surgeon does not allow safe device introduction.

Related Conditions & MeSH terms

• Gastroesophageal Reflux
• Gastroesophageal Reflux Disease
• Hernia, Hiatal
• Hiatal Hernia

Intervention

Device:
• TIF Transoral Fundoplication
A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)

Other:
• Sham placebo procedure
The Sham Procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.

Locations

Country	Name	City	State
United States	Northwestern University	Chicago	Illinois
United States	Ohio State University Hospital	Columbus	Ohio
United States	SurgOne PC	Englewood	Colorado
United States	University of Texas, Health Science Center at Houston	Houston	Texas
United States	Cedars Sinai Medical Center	Los Angeles	California
United States	Oregon Health and Science University	Portland	Oregon
United States	The Oregon Clinic	Portland	Oregon
United States	Reston Surgical Associates	Reston	Virginia
United States	University of Washington	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
EndoGastric Solutions

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With a Clinically Significant Reduction in Gastroesophageal Reflux Disease (GERD) Symptoms (Specifically "Troublesome" Regurgitation With or Without Heartburn as Assessed by the RDQ Per the Montreal Consensus Definition,	Primary efficacy Hypothesis 1: At 6-month follow-up, the proportion of Transesophageal Incisionless Fundoplication (TIF)2+Placebo pts who are free of "troublesome" symptoms will be statistically significantly larger than those randomized to the Sham+PPI (Proton Pump Inhibitor) treatment group.	6 month follow up
Secondary	Normalization of Esophageal Acid Exposure - as Measured by DeMeester Score	DeMeester Score is a composite score taking into consideration reflux episodes, percentage of time pH is < 4 and others. DMS was first reported in 1974 by Johnson and DeMeester. It is a composite score that measures acid exposure during prolonged ambulatory pH monitoring. The parameters that constitute the score are: total number of episodes of reflux, - reflux is undesirable, therefore lower numbers are better, higher numbers are worse. Ideally there would be zero reflux episodes.; % total time esophageal pH < 4, upright position and supine position, respectively - pH < 4 is undesirable, therefor lower percentages are better; number of episodes longer than 5 minutes, - lower is better; maximal reflux duration, (reflux is undesirable - lower is better; total percentage of time with pH below 4 - below 4 is undesirable - lower is better; The composite score can be obtained by adding the scores calculated for each of the six components.	6 months post procedure